Xie Hao, Shi Bin, Fan Junzhen, Liu Shui, Ma Qiaozhi, Dai Junnan, Dong Siqing, Liu Ying, Meng Han, Liu Hui, Yang Ya, Mu Xuetao
Postgraduate Training Base of the Third Medical Center of Chinese PLA General Hospital, Jinzhou Medical University, Beijing, China.
Department of Radiology, the Jintang First People's Hospital, Chengdu, China.
J Gastrointest Oncol. 2024 Oct 31;15(5):2187-2200. doi: 10.21037/jgo-24-347. Epub 2024 Oct 29.
Disease-free survival (DFS) is an essential indicator for evaluating the prognosis of liver transplantation (LT) in hepatocellular carcinoma (HCC) patients. Despite progress in the prediction of DFS by radiomics, only preoperative clinical features have been combined in most studies. The aim of this study was to construct a nomogram model (NM) using preoperative clinical features, radiomics, and postoperative pathological indicators for more effective prediction of DFS.
This was a retrospective study of a single-center cohort comprising 139 HCC patients. Using the whole cohort, we constructed and assessed a clinical model (CM) based on alpha-fetoprotein (AFP) and alkaline phosphatase (ALP), a pathological model (PM) based on Ki-67 and tumor number, a radiomics model (RM) based on the radiomics score (Rad-score), and an NM based on the above five independent predictors.
Significant correlations between the NM and DFS were observed in the training and validation cohorts. Among the four prediction models, the C-index of the NM was the highest [(training/validation cohort) CM: 0.664/0.676, PM: 0.737/0.691, RM: 0.706/0.697, NM: 0.817/0.760], and the areas under the receiver operating characteristic curves (AUCs) of the NM prediction of 1-year, 2-year, and 3-year DFS were also the highest [(training/validation cohort) 1-year, 2-year, and 3-year CM: 0.726/0.726, 0.685/0.744, 0.645/0.686, PM: 0.789/0.780, 0.801/0.748, 0.841/0.735, RM: 0.769/0.752, 0.717/0.805, 0.748/0.765, NM: 0.882/0.854, 0.867/0.849, 0.882/0.801]. The NM also exhibited the highest net clinical benefit.
Based on radiomics, clinical features, and pathological indicators, the NM could be used to effectively predict DFS after LT in HCC patients, guiding the follow-up and complementary treatment.
无病生存期(DFS)是评估肝细胞癌(HCC)患者肝移植(LT)预后的重要指标。尽管在通过放射组学预测DFS方面取得了进展,但大多数研究仅结合了术前临床特征。本研究的目的是构建一个列线图模型(NM),使用术前临床特征、放射组学和术后病理指标来更有效地预测DFS。
这是一项对139例HCC患者的单中心队列回顾性研究。利用整个队列,我们构建并评估了基于甲胎蛋白(AFP)和碱性磷酸酶(ALP)的临床模型(CM)、基于Ki-67和肿瘤数量的病理模型(PM)、基于放射组学评分(Rad-score)的放射组学模型(RM)以及基于上述五个独立预测因子的NM。
在训练和验证队列中观察到NM与DFS之间存在显著相关性。在四个预测模型中,NM的C指数最高[(训练/验证队列)CM:0.664/0.676,PM:0.737/0.691,RM:0.706/0.697,NM:0.817/0.760],并且NM预测1年、2年和3年DFS的受试者工作特征曲线下面积(AUC)也最高[(训练/验证队列)1年、2年和3年CM:0.726/0.726,0.685/0.744,0.645/0.686,PM:0.789/0.780,0.801/0.748,0.841/0.735,RM:0.769/0.752,0.717/0.805,0.748/0.765,NM:0.882/0.854,0.867/0.849,0.882/0.801]。NM还表现出最高的净临床效益。
基于放射组学、临床特征和病理指标,NM可用于有效预测HCC患者LT术后的DFS,指导随访和辅助治疗。